HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unilever Hit With Class Action Over Mercury-Laced Cream Originating In Mexico

Executive Summary

According to the plaintiff, Unilever’s Pond’s Rejuveness Anti-Wrinkle Cream is defective insofar as tested product has been found to contain unlabeled mercury, constituting negligence that has resulted in user injuries. The plaintiff seeks certification of a transnational class and compensatory and punitive damages, among other relief.

You may also be interested in...



US Appropriators Seek FDA Reports On ‘Toxic’ Cosmetic Chemicals, ‘Natural’ Cosmetics

The FDA must report to the House Appropriations Committee on any work toward defining “natural” cosmetics and on the health effects of talc, asbestos and lead in cosmetic products. The committee’s 2021 FDA spending bill report also cites concerns about skin-lightening products containing “dangerous levels of mercury and hydroquinone.”

Class Action Watch: Plaintiffs Target L’Oreal’s Pump-Dispensed Liquid Cosmetics, GNC’s Vitamin E Oil

According to a class action complaint filed in California’s Northern District, L’Oreal shortchanges consumers by packaging liquid makeup offerings so that users cannot access significant amounts of product. Meanwhile, the authenticity of GNC’s Vitamin E Skin Oil is being challenged in another California federal court, and Unilever ducks a class action in Texas concerning mercury in Pond’s Rejuveness.

Inner Glow Vitamins Launches Latest Sun Protection In A Pill

Sun protection is not an unheard-of claim in the dietary supplement space, but it has proven a problematic one from regulatory and legal standpoints.

Topics

Related Companies

UsernamePublicRestriction

Register

RS149642

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel